Latham & Watkins Advises Health Catalyst on Divestiture of Vitalware

Health Catalyst, Inc. (Health Catalyst or the company) (Nasdaq: HCAT) has announced it has signed a definitive agreement to divest Vitalware, LLC and the Vitalware business unit, its mid‑revenue cycle business, to Med‑Metrix. This divestiture sharpens Health Catalyst’s focus on driving measurable improvement for health systems across cost, clinical, and consumer performance, and the company expects it to accelerate the broader transformation underway.

Latham & Watkins LLP represents Health Catalyst in the transaction with a corporate team led by Bay Area partner Tessa Bernhardt, with associates Rebecca Dixon, Kelsey MacKinnon, and Judy Shamshikh. Advice was also provided on corporate and capital markets matters by Bay Area partners Rick Kline and Erica Kassman, with associates Julian Brody and Kayleigh Kuyon; on benefits matters by Bay Area partner Ashley Wagner, with associate Will Fowler; on intellectual property matters by Bay Area partner Michelle Gross, with associates Ryan Sanders, Julian Savelski, Claire Jensen, Karen Lee, and Rachel Oh; on data privacy matters by Bay Area partner Heather Deixler, with associate Chad Leiper; on tax matters by Bay Area partner Grace M. Lee, with associate Jacob Meninga; on antitrust matters by Bay Area partner Kelly Fayne; on healthcare and life sciences matters by Bay Area partner Betty Pang; on representation and warranty insurance matters by Los Angeles partner Harrison White; and on finance matters by New York/Los Angeles partner Nathan Whitaker and Washington, D.C. partner Jennifer Kent, with associates Hyunji Lee, Samantha Kosarzycki, and Edgar (Ted) Mathiowetz.